NEW YORK, NY / ACCESS Newswire / February 17, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=130078&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 17, 2025 / If you suffered a loss on your FTAI Aviation Ltd. (NASDAQ:FTAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ftai-aviation-ltd-lawsuit-submission-form?prid=130076&wire=1 or contact Joseph E.

NEW YORK, NY / ACCESS Newswire / February 17, 2025 / If you suffered a loss on your Block, Inc. (NYSE:XYZ) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/block-inc-lawsuit-submission-form-2?prid=130074&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 17, 2025 / If you suffered a loss on your Cardlytics, Inc. (NASDAQ:CDLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cardlytics-lawsuit-submission-form?prid=130071&wire=1 or contact Joseph E. Levi, Esq.

PHILADELPHIA, PA / ACCESS Newswire / February 17, 2025 / Kehoe Law Firm, P.C. is investigating whether certain executive officers and directors of Autodesk, Inc. ("Autodesk" or the "Company") (NASDAQ:ADSK) breached their fiduciary duties by failing to manage Autodesk in an acceptable manner and whether Autodesk and its shareholders were harmed as a result.

NEW YORK, NY / ACCESS Newswire / February 17, 2025 / If you suffered a loss on your Transocean Ltd. (NYSE:RIG) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/transocean-ltd-lawsuit-submission-form?prid=130072&wire=1 or contact Joseph E.

NEW YORK, NY / ACCESS Newswire / February 17, 2025 / If you suffered a loss on your Joint Stock Company Kaspi.kz (NASDAQ:KSPI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/joint-stock-company-kaspi-kz-lawsuit-submission-form?prid=130070&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 17, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=130075&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 17, 2025 / If you suffered a loss on your Caribou Biosciences, Inc. (NASDAQ:CRBU) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/caribou-biosciences-inc-lawsuit-submission-form?prid=130073&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired stock of Venture Global, Inc. (“Venture” or the “Company”) (NYSE: VG) pursuant and/or traceable to Venture's registration statement for the initial public offering held on or about January 24, 2025. You are hereby notified that the class action lawsuit Gerald Bowes v.

LyondellBasell's strong dividend track record and a 7% yield make it attractive for dividend investors, despite recent stock underperformance. Updated fair value for LYB is $115 per share, reflecting a slight increase in WACC and a lower dividend growth assumption. LYB's CLCS segment shows exceptional growth potential, with plans to significantly increase production and EBITDA by 2030.

Santa Clara, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Santa Clara, California - Interview Kickstart, a leader in technical interview preparation and advanced training programs, has launched its new flagship machine learning (ML) course, designed to prepare professionals for competitive roles at FAANG+ companies and other tech industry giants. To learn more visit: https://www.interviewkickstart.com/courses/machine-learning-course This new course equips candidates with cutting-edge skills and expertise to excel in the rapidly growing field of machine learning and artificial intelligence.

NEW YORK CITY, NY / ACCESS Newswire / February 17, 2025 / WHY: New York, N.Y., February 17, 2025.

Ardmore Shipping's Q4-2024 earnings dropped 60% year-on-year due to lower spot day rates, but full-year earnings increased, showcasing resilience. The company has strong fundamentals, including a low cash breakeven rate of $11.5k/day and high liquidity, making it financially robust. Favorable market dynamics, such as rising demand for tankers and limited vessel supply, support Ardmore's potential for future growth.

Robinhood Markets (HOOD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

AppLovin (APP) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

IREN Limited (IREN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Upstart (UPST) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

SAN FRANCISCO, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is facing mounting pressure on multiple fronts. Following disappointing sales figures and ongoing legal challenges, analysts TD Cowen recently lowered its price target for Regeneron to $1,030 from $1,230. The downward revision reflects preannounced January figures for EYLEA®, a key product in Regeneron's portfolio, with TD Cowen citing increased competition in the market and significantly lowering its revenue estimates for the EYLEA® franchise.

Coinbase's efforts to accelerate growth, increase market share and continue innovation poise it well for growth, making it a great choice for one's portfolio.